Plain-English translation of NCT05254314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether semaglutide, a medication commonly used to help people lose weight, can also help control asthma symptoms in adults who have obesity and asthma that isn't fully controlled by their current inhalers. Researchers believe that weight loss and reduced inflammation from this medication might make it easier to breathe and reduce asthma flare-ups. Half the participants will receive the actual medication, and half will receive a placebo (a harmless injection with no active drug) to fairly compare results.
Many people with asthma also have obesity, and extra weight can make asthma symptoms worse. Currently, there aren't many treatment options that address both conditions at once. This study explores whether this medication might help by reducing weight and the inflammation in the airways that triggers asthma symptoms.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic for a 4-week initial monitoring period where researchers assess your current asthma and collect baseline information. Then you would receive either the medication or placebo as a weekly injection for 24 weeks while continuing your regular asthma inhalers. During this time, you'll have clinic visits to answer questions about your asthma symptoms, complete breathing tests, and provide blood samples to measure inflammation. After the 24-week treatment period ends, you'll have a final 2-week monitoring period to ensure you're doing well.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States